Key statistics dashboard for BioXcel Therapeutics, Inc. (BTAI). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology.
Stock Data
| Price | $0.07 |
| Market Cap | $2M |
| Enterprise Value | $93.9M |
| Beta | 0.30 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.01 |
| Price / Book | -0.01 |
| P/S | 3.08 |
| EV/EBITDA | -1.76 |
| EV/Sales | 126.54 |
| EV/FCF | -1.84 |
| P/FCF | -0.04 |
| Earnings Yield | -7854.39% |
| FCF Yield | -2230.82% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 45.28% |
| EBIT Margin | -7228.57% |
| EBITDA Margin | -7198.25% |
| Operating Margin | -6014.42% |
| Net Margin | -9549.87% |
| Return on Equity | 69.92% |
| Return on Assets | -246.05% |
| Return on Invested Capital | 1144.58% |
| Return on Capital Employed | 41.19% |
Financial Health
| Current Ratio | 0.21 |
| Quick Ratio | 0.21 |
| Cash Ratio | 0.09 |
| Debt / Equity | -0.90 |
| Debt / Assets | 362.69% |
| Net Debt / EBITDA | -1.72 |
| Interest Coverage | -2.59 |
Per-Share Data
| Revenue per share | 0.06 |
| Book Value per share | -9.46 |
| Cash per share | 1.05 |
| FCF per share | -4.17 |
| Tangible Book Value per share | -9.46 |
| Dividend per share | 0.00 |
Related companies: ANVS · BCAB · CELU · EVAX · GBIO · MAIA · MURA
Explore sector: Healthcare · Biotechnology
More sections of BTAI: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks